{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:43:17Z","timestamp":1759693397561,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.mehy.2020.110450","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T02:02:28Z","timestamp":1607133748000},"page":"110450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Could Galectin-3 be a key player in the etiology of neuromyelitis optica spectrum disorder?"],"prefix":"10.1016","volume":"146","author":[{"given":"Pooja","family":"Ramakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mehy.2020.110450_b0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9451","key":"10.1016\/j.mehy.2020.110450_b0010","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"The Lancet"},{"key":"10.1016\/j.mehy.2020.110450_b0015","doi-asserted-by":"crossref","unstructured":"Bukhari W, Barnett M, Prain K, Broadley S. Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci 2012; 13: 12970\u201312993.","DOI":"10.3390\/ijms131012970"},{"issue":"9","key":"10.1016\/j.mehy.2020.110450_b0020","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.biocel.2012.06.013","article-title":"Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies","volume":"44","author":"Ratelade","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.mehy.2020.110450_b0025","doi-asserted-by":"crossref","unstructured":"Soltys J, Liu Y, Ritchie A, Wemlinger S, Schaller K, Schumann H, Owens G, Bennett J. Membrane assembly of aquaporin\u20134 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Invest 2019; 129: 2000-2013.","DOI":"10.1172\/JCI122942"},{"key":"10.1016\/j.mehy.2020.110450_b0030","doi-asserted-by":"crossref","unstructured":"Lucchinetti CF, Mandler RN, McGavern D et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002 125(Pt 7):1450-61.","DOI":"10.1093\/brain\/awf151"},{"key":"10.1016\/j.mehy.2020.110450_b0035","doi-asserted-by":"crossref","unstructured":"Hayashida S, Masaki K, Suzuki SO et al. Distinct microglial and macrophage distribution patterns in the concentric and lamellar lesions in Bal\u00f3's disease and neuromyelitis optica spectrum disorders. Brain Pathol. 2020 Sep 9.","DOI":"10.1111\/bpa.12898"},{"key":"10.1016\/j.mehy.2020.110450_b0040","doi-asserted-by":"crossref","unstructured":"da Fonseca A, Matias D, Garcia C, Amaral R, Geraldo L, Freitas C, Lima F. The impact of microglial activation on blood\u2013brain barrier in brain diseases. Front Cell Neurosci 2014; 8: 362.","DOI":"10.3389\/fncel.2014.00362"},{"issue":"7","key":"10.1016\/j.mehy.2020.110450_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1716-9","article-title":"Microglia-derived TNF-\u03b1 mediates endothelial necroptosis aggravating blood brain\u2013barrier disruption after ischemic stroke","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.mehy.2020.110450_b0050","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fncel.2018.00494","article-title":"Activated microglia disrupt the blood-brain barrier and induce chemokines and cytokines in a rat in vitro model","volume":"12","author":"Shigemoto-Mogami","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.mehy.2020.110450_b0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-017-0428-6","article-title":"Myelin-specifc multiple sclerosis antibodies cause complement\u2013dependent oligodendrocyte loss and demyelination","volume":"5","author":"Liu","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"10.1016\/j.mehy.2020.110450_b0060","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/glia.23512","article-title":"Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica","volume":"66","author":"Liu","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.mehy.2020.110450_b0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.conb.2017.10.001","article-title":"Microglia: origins, homeostasis, and roles in myelin repair","volume":"47","author":"Lloyd","year":"2017","journal-title":"Curr Opin Neurobiol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110450_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrc1527","article-title":"Galectins as modulators of tumour progression","volume":"5","author":"Liu","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.mehy.2020.110450_b0075","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.celrep.2015.02.012","article-title":"Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation","volume":"10","author":"Burguillos","year":"2015","journal-title":"Cell Reports"},{"key":"10.1016\/j.mehy.2020.110450_b0080","doi-asserted-by":"crossref","unstructured":"Srejovic I, Selakovic D, Jovicic N, Jakovljevi\u0107 V, Lukic ML, Rosic G. Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior. Biomolecules 2020;10(5):798.","DOI":"10.3390\/biom10050798"},{"key":"10.1016\/j.mehy.2020.110450_b0085","doi-asserted-by":"crossref","unstructured":"Reichert F, Rotshenker S. Galectin-3 (MAC-2) Controls microglia phenotype whether amoeboid and phagocytic or branched and non-phagocytic by regulating the cytoskeleton. Front Cell Neurosci. 2019; 13:90.","DOI":"10.3389\/fncel.2019.00090"},{"issue":"30","key":"10.1016\/j.mehy.2020.110450_b0090","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.1523\/JNEUROSCI.1498-12.2012","article-title":"Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury","volume":"32","author":"Lalancette-Hebert","year":"2012","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.mehy.2020.110450_b0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41418-019-0348-z","article-title":"Galectin-3 promotes A\u03b2 oligomerization and A\u03b2 toxicity in a mouse model of Alzheimer\u2019s disease","volume":"27","author":"Tao","year":"2020","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.mehy.2020.110450_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11441-0","article-title":"Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington\u2019s disease","volume":"10","author":"Siew","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.mehy.2020.110450_b0105","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4049\/jimmunol.182.2.1167","article-title":"Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis","volume":"182","author":"Jiang","year":"2009","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.mehy.2020.110450_b0110","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/brb3.75","article-title":"Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis","volume":"2","author":"Lerman","year":"2012","journal-title":"Brain Behav"},{"issue":"12","key":"10.1016\/j.mehy.2020.110450_b0115","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3109\/00207454.2016.1163550","article-title":"Th17 cells in neuromyelitis optica spectrum disorder: a review","volume":"126","author":"Lin","year":"2016","journal-title":"Int J Neurosci"},{"issue":"4","key":"10.1016\/j.mehy.2020.110450_b0120","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ajpath.2013.06.017","article-title":"Galectin-3 modulates Th17 responses by regulating dendritic cell cytokines","volume":"183","author":"Fermin Lee","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.mehy.2020.110450_b0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fncel.2018.00297","article-title":"Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination","volume":"12","author":"Thomas","year":"2018","journal-title":"Front Cell Neurosci"},{"issue":"8","key":"10.1016\/j.mehy.2020.110450_b0130","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4103\/1673-5374.253521","article-title":"Galectin-3 prospects as a therapeutic agent for multiple sclerosis","volume":"14","author":"Thomas","year":"2019","journal-title":"Neural Regen Res"},{"issue":"9","key":"10.1016\/j.mehy.2020.110450_b0135","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1074\/jbc.M107668200","article-title":"Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest","volume":"277","author":"Yoshii","year":"2002","journal-title":"J Biol Chem"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720333417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720333417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:27:00Z","timestamp":1759692420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720333417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":27,"alternative-id":["S0306987720333417"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110450","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could Galectin-3 be a key player in the etiology of neuromyelitis optica spectrum disorder?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110450"}}